The Carmel office of Arthur J. Gallagher & Co. just made its sixth acquisition in five years, and it expects looming changes to tax and health laws to produce even more chances to snap up benefits brokers this year.
Amylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly and Co. co-developed the drug, but ended its partnership with Amylin last year.
The Indiana House has added an 18-month exemption for bars to a bill calling for a broad statewide smoking ban.
Health insurer WellPoint Inc. plans to improve primary care reimbursement and start paying for care management it doesn’t currently cover, changes that could give patients more quality time with their doctors.
The Indiana House has approved a bill that would broaden the state's ban on synthetic drugs to include compounds nicknamed "bath salts" and others that mimic marijuana.
The Indianapolis-based health insurer reported earnings of $335.3 million, or 96 cents per share, down 39 percent from the same quarter a year ago.
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
Something doesn’t add up about Arcadia Resources Inc.’s agreement to sell its pharmacy business for a low price of $2 million, according to many of the Indianapolis company’s investors.
U.S. medical device makers have spent the last year urging government officials to approve high-risk products faster, like their European counterparts. A scandal over leaking breast implants made in France, however, may make the argument more difficult.
Eli Lilly and Co. has won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper marketing of the company's best-selling medication, Zyprexa, raised their costs.
A new onslaught of Medicare data might shine more light on providers, but tricky questions abound.
AIT Laboratories, one of the area’s fastest-growing companies in recent years, confirmed Tuesday that it is eliminating jobs, but would not say how many. The company said it is restructuring.
A California-based pharmaceutical company says it expects to hire 234 people by 2016 at a new operation on the site of a former Pfizer Inc. drug plant near Terre Haute.
Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.
Fifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES for millions of pregnant women from about 1938 to the early 1970s.
Frontier Capital in Charlotte, N.C., provided the funding that will support the continued expansion of Healthx, a local provider of online health care portals.
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
Insurance companies spent millions of dollars trying to defeat the U.S. health-care overhaul. But profit margins at the companies have widened to levels not seen since before the recession, a Bloomberg Government study shows.
Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a wide margin, sending shares down.
Drugstore operator Walgreen Co. said Thursday it expects to lose almost 90 percent of prescriptions handled by pharmacy benefits manager Express Scripts Inc. after it leaves Express Scripts' networks on Jan. 1.
